Clinical trial NCT03169803: Cardiac Output Autonomic Stimulation Therapy for Acute Heart Failure (COAST-AHF)
Official title: Cardiac Output Autonomic Stimulation Therapy for Acute Heart Failure (COAST-AHF) - System Design Study
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Heart Failure Acute
Keywords: Electrical Stimulation Therapy
Electrodes
Parasympathetic Nervous System
Sympathetic Fibers
Post Ganglionic
Congestive Heart Failure
Heart Failure
Lead sponsor: NeuroTronik Inc.
Sponsor class: INDUSTRY
First posted: 2017-05-30
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DEVICE_FEASIBILITY

Brief summary: A feasibility study to investigate the safety and performance of the NeuroTronik Cardiac Autonomic Nerve Stimulation (CANS) Therapy System

Detailed description: A single-arm, safety study intended to assess safety and system performance, and the feasibility to improve hemodynamics in patients with acute heart failure syndrome using transvenous, cardiac autonomic nerve stimulation (CANS) therapy. In addition, the effects of NeuroTronik CANS Therapy™ on the congestion of patients will be studied. The study proposes that the NeuroTronik CANS Therapy™ System be deployed during the acute heart failure syndrome hospital admission, along with existing standard treatment.

Eligibility criteria: Inclusion Criteria:

1. Left Ventricular Ejection fraction \< 40%, measured in the last year
2. At least two of the following:

   * Pulmonary Capillary Wedge Pressure \> 18 mmHg
   * Pulmonary congestion on Chest X-ray
   * Jugular vein distension
   * Pulmonary rales
   * Edema
   * Dyspnea at rest
   * Two (2) emergency room visits or hospital admissions in the past three (3) months, or three (3) emergency room visits or admissions in the past six (6) months requiring intravenous diuretics, ultrafiltration or in-hospital inotropic therapy.
3. With or without evidence of low perfusion

Exclusion Criteria:

1. Systolic Blood Pressure \< 90 mmHg or \> 160 mmHg
2. Catecholamine or inotropic therapy within the previous 48 hours
3. Levosimendan within the previous 72 hours
4. Chronic outpatient catecholamine or inotropic therapy
5. Presence of implanted pacemaker, implantable cardioverter defibrillator or cardiac resynchronization therapy device
6. Presence of or prior vagal nerve stimulator
7. Coronary artery bypass graft surgery, percutaneous coronary intervention, acute myocardial infarction, or valve replacement within prior 1 month
8. Second or third degree heart block
9. History of atrial or ventricular arrhythmias
10. History of mitral or aortic valve stenosis or regurgitation
11. Hypertrophic obstructive or infiltrative cardiomyopathy
12. Prior vagotomy
13. Prior heart transplant
14. Narrow angle glaucoma
15. Renal failure - either on dialysis or serum creatinine \> 2.0 mg/dl
16. Hepatic failure - bilirubin, serum glutamic oxaloacetic transaminase, or serum glutamic pyruvic transaminase \> four times upper limit of normal
17. Life expectancy \< 12 months per physician judgment
18. Women who are pregnant
19. Allergy to fentanyl, midazolam, propofol, eggs, egg products, soybeans, or soy products
20. Subjects unwilling or unable to provide consent

Primary outcomes:
measure: Arterial blood pressure
timeFrame: 24 hours
measure: Heart Rate
timeFrame: 24 hours
Secondary outcomes:
measure: Cardiac output
timeFrame: 24 hours
measure: Pulmonary capillary wedge pressure
timeFrame: 24 hours
Other outcomes:
Locations:
city: Panama City
country: Panama
facility: Hospital Punta Pacífica
Study officials:
affiliation: Hospital Punta Pacífica, Panama City, Panama
name: Temístocles Díaz, MD
role: PRINCIPAL_INVESTIGATOR
References: